Navigation Links
Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
Date:11/12/2013

CRANBURY, N.J., Nov. 12, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office today issued two new patents to Palatin.  Both patents support Palatin's program developing synthetic mimetics of the neuropeptide hormone atrial natriuretic peptide. These mimetics may be useful in treatment of acute asthma, other pulmonary diseases, heart failure, hypertension and other indications.

U.S. Patent 8,580,747, entitled "Cyclic Natriuretic Peptide Constructs," has composition of matter claims relating to Palatin's PL-3994 natriuretic peptide receptor-A agonist for treatment of cardiovascular and pulmonary indications.  PL-3994 has completed two early stage human clinical studies, a Phase 1 trial in healthy volunteers and a Phase 2A trial in volunteers with controlled hypertension.

U.S. Patent 8,580,746, entitled "Amide Linkage Cyclic Natriuretic Peptide Constructs," has composition of matter claims to a novel series of mimetics of atrial natriuretic peptide.  These compounds have potential utility in a number of cardiovascular and pulmonary indications.

"We are pleased to have two new issued patents supporting our natriuretic peptide portfolio.  Our mimetic peptides have a much longer half-life than endogenous atrial natriuretic peptide, giving them important drug-like properties," stated Carl Spana, Ph.D., President and CEO of Palatin.

The issued patents have a twenty-year term that will not expire until March 2027.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about potential clinical utility of synthetic mimetics of the neuropeptide hormone atrial natriuretic peptide, whether the subject patents will adequately protect against competition, the future status of pending and planned patent applications, potential clinical trial results, potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), regulatory plans, development programs, proposed indications for synthetic natriuretic peptide receptor-A agonist product candidates and market potential for synthetic natriuretic peptide receptor-A agonist product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of nonclinical, preclinical and toxicology studies, result of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
6. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
7. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
11. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):